Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 549


Metabolomic effects of androgen deprivation therapy treatment for prostate cancer.

Chi JT, Lin PH, Tolstikov V, Oyekunle T, Chen EY, Bussberg V, Greenwood B, Sarangarajan R, Narain NR, Kiebish MA, Freedland SJ.

Cancer Med. 2020 Mar 31. doi: 10.1002/cam4.3016. [Epub ahead of print]


Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.

Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Pra AD, Mahal BA, Morgan TM, Mehra R, Kaffenberger S, Salami SS, Kane C, Pollack A, Den RB, Berlin A, Schaeffer EM, Nguyen PL, Feng FY, Spratt DE.

Prostate Cancer Prostatic Dis. 2020 Mar 30. doi: 10.1038/s41391-020-0226-2. [Epub ahead of print]


Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.

Vidal AC, Duong F, Howard LE, Wiggins E, Freedland SJ, Bhowmick NA, Gong J.

Anticancer Res. 2020 Mar;40(3):1459-1462. doi: 10.21873/anticanres.14088.


Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS.

Prostate Cancer Prostatic Dis. 2020 Feb 28. doi: 10.1038/s41391-020-0213-7. [Epub ahead of print]


A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2).

Freedland SJ, Allen J, Jarman A, Oyekunle T, Armstrong AJ, Moul JW, Sandler H, Posadas EM, Levin D, Wiggins E, Howard LE, Wu Y, Lin PH.

Clin Cancer Res. 2020 Feb 27. pii: clincanres.3873.2019. doi: 10.1158/1078-0432.CCR-19-3873. [Epub ahead of print]


Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data.

Wallis CJD, Lawson K, Butaney M, Satkunasivam R, Parikh J, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

Jpn J Clin Oncol. 2020 Feb 21. pii: hyaa021. doi: 10.1093/jjco/hyaa021. [Epub ahead of print]


27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.

Dambal S, Alfaqih M, Sanders S, Maravilla E, Ramirez-Torres A, Galvan GC, Reis-Sobreiro M, Rotinen M, Driver LM, Behrove MS, Talisman TJ, Yoon J, You S, Turkson J, Chi JT, Freeman MR, Macias E, Freedland SJ.

Mol Cancer Res. 2020 Feb 4. doi: 10.1158/1541-7786.MCR-19-0974. [Epub ahead of print]


Partial Validation of the Sleep Health Construct in the Medical Outcomes Study Sleep Questionnaire.

Bliwise DL, Howard LE, Moreira DM, Andriole GL, Hopp ML, Freedland SJ.

J Clin Psychol Med Settings. 2020 Jan 22. doi: 10.1007/s10880-020-09699-4. [Epub ahead of print]


Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study.

Johnston AW, Longo TA, Davis LG, Zapata D, Freedland SJ, Routh JC.

Int Braz J Urol. 2020 Jan-Feb;46(1):42-52. doi: 10.1590/S1677-5538.IBJU.2019.0225.


Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.

Howard LE, Zhang J, Fishbane N, Hoedt AM, Klaassen Z, Spratt DE, Vidal AC, Lin D, Hitchins MP, You S, Freeman MR, Yamoah K, Davicioni E, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Dec 16. doi: 10.1038/s41391-019-0197-3. [Epub ahead of print]


Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities.

Zhu Y, Freedland SJ, Ye D.

Prostate Cancer Prostatic Dis. 2019 Dec 6. doi: 10.1038/s41391-019-0193-7. [Epub ahead of print] No abstract available.


Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data.

Butaney M, Satkunasivam R, Goldberg H, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z, Wallis CJD.

Am J Clin Oncol. 2020 Mar;43(3):193-202. doi: 10.1097/COC.0000000000000650.


Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.

Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA.

Clin Cancer Res. 2020 Mar 1;26(5):1086-1093. doi: 10.1158/1078-0432.CCR-19-2853. Epub 2019 Nov 21.


Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.

Schwarzman LS, Pagani RL, Ohlander SJ, Mima M, Abern MR, Andriole GL, Freedland SJ, Moreira DM.

Urology. 2020 Mar;137:97-101. doi: 10.1016/j.urology.2019.11.004. Epub 2019 Nov 14.


Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools.

Tolksdorf J, Kattan MW, Boorjian SA, Freedland SJ, Saba K, Poyet C, Guerrios L, De Hoedt A, Liss MA, Leach RJ, Hernandez J, Vertosick E, Vickers AJ, Ankerst DP.

BMC Med Res Methodol. 2019 Oct 15;19(1):191. doi: 10.1186/s12874-019-0839-0.


Reply by Authors.

Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

J Urol. 2020 Jan;203(1):127. doi: 10.1097/01.JU.0000604076.44320.a0. Epub 2019 Oct 14. No abstract available.


High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, DʼAmico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M.

Nat Commun. 2019 Sep 25;10(1):4358. doi: 10.1038/s41467-019-12298-z.


Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM.

Clin Cancer Res. 2019 Nov 15;25(22):6721-6730. doi: 10.1158/1078-0432.CCR-19-1587. Epub 2019 Sep 12.


The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder.

Kerr PS, Freedland SJ, Williams SB.

Expert Rev Mol Diagn. 2020 Feb;20(2):127-129. doi: 10.1080/14737159.2019.1665509. Epub 2019 Sep 9. No abstract available.


Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Allott EH, Csizmadi I, Howard LE, Muller RL, Moreira DM, Andriole GL, Roehrborn CG, Freedland SJ.

BJU Int. 2020 Feb;125(2):226-233. doi: 10.1111/bju.14905. Epub 2019 Sep 27.


Racial Discrepancies in Overall Survival among Men Treated with 223Radium.

Zhao H, Howard LE, De Hoedt A, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ.

J Urol. 2020 Feb;203(2):331-337. doi: 10.1097/JU.0000000000000524. Epub 2019 Sep 3.


Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.

Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

J Urol. 2020 Jan;203(1):120-127. doi: 10.1097/JU.0000000000000494. Epub 2019 Aug 20.


Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.

Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB.

Eur Urol Oncol. 2019 Sep;2(5):497-504. doi: 10.1016/j.euo.2018.07.009. Epub 2018 Aug 17.


Dietary intake and prostate cancer, continued pursuit for evidence.

Lin PH, Freedland SJ.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S246-S249. doi: 10.21037/tau.2019.01.08. No abstract available.


Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Tablazon IL, Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ, Williams SB.

Cancer. 2019 Nov 15;125(22):4003-4010. doi: 10.1002/cncr.32414. Epub 2019 Aug 7.


Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy.

Vidal AC, Howard LE, Wiggins E, De Hoedt AM, Shiao SL, Knott S, Taioli E, Fowke JH, Freedland SJ.

Cancer Epidemiol. 2019 Oct;62:101578. doi: 10.1016/j.canep.2019.101578. Epub 2019 Aug 1.


Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.

Wang J, Xu W, Mierxiati A, Huang Y, Wei Y, Lin G, Dai B, Freedland SJ, Qin X, Zhu Y, Ye DW.

Prostate. 2019 Sep;79(13):1563-1571. doi: 10.1002/pros.23878. Epub 2019 Aug 2.


Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis.

Wallis CJD, Satkunasivam R, Butaney M, Khan UA, Goldberg HA, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

Am J Clin Oncol. 2019 Sep;42(9):711-716. doi: 10.1097/COC.0000000000000577.


The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population.

Skove SL, Howard LE, Senechal J, De Hoedt A, Bresee C, Cunningham TJ, Barbour KE, Kim J, Freedland SJ, Anger JT.

Neurourol Urodyn. 2019 Sep;38(7):1966-1972. doi: 10.1002/nau.24100. Epub 2019 Jul 14.


Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH.

Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ.

Asian J Urol. 2019 Jul;6(3):242-248. doi: 10.1016/j.ajur.2019.01.004. Epub 2019 Jan 18.


Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?

Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Clin Genitourin Cancer. 2019 Oct;17(5):e930-e938. doi: 10.1016/j.clgc.2019.05.007. Epub 2019 May 24.


Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.

Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G, Gan H, Freedland SJ, Zhu Y, Ye D.

Eur Urol. 2019 Sep;76(3):280-283. doi: 10.1016/j.eururo.2019.06.004. Epub 2019 Jun 24.


Obesity, visceral adiposity, and prostate cancer: What is the role of lifestyle interventions?

Shirazipour CH, Freedland SJ.

Cancer. 2019 Aug 15;125(16):2730-2731. doi: 10.1002/cncr.32165. Epub 2019 Jun 10. No abstract available.


Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB.

JAMA Surg. 2019 Jun 5:e191629. doi: 10.1001/jamasurg.2019.1629. [Epub ahead of print]


Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.


African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8.


Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy.

Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2019 Sep 1;125(17):3025-3032. doi: 10.1002/cncr.32168. Epub 2019 May 1.


Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer.

Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):633-635. doi: 10.1038/s41391-019-0146-1. Epub 2019 Apr 29.


Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.

Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.

Cancer. 2019 Aug 15;125(16):2861-2867. doi: 10.1002/cncr.32141. Epub 2019 Apr 29. Erratum in: Cancer. 2019 Dec 15;125(24):4544.


Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men.

Vidal AC, Oyekunle T, Howard LE, Shivappa N, De Hoedt A, Figueiredo JC, Taioli E, Fowke JH, Lin PH, Hebert JR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):580-587. doi: 10.1038/s41391-019-0143-4. Epub 2019 Apr 12.


Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.

Freitas D, Andriole GL, Freedland SJ, Neto BS, Moreira DM.

Urology. 2019 Jul;129:160-164. doi: 10.1016/j.urology.2019.02.034. Epub 2019 Mar 23.


MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):531-538. doi: 10.1038/s41391-019-0134-5. Epub 2019 Feb 25.


Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men.

Fowke JH, Koyama T, Dai Q, Zheng SL, Xu J, Howard LE, Freedland SJ.

Cancer Lett. 2019 May 1;449:99-105. doi: 10.1016/j.canlet.2019.02.023. Epub 2019 Feb 15.


The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.

Freitas DMO, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

Scand J Urol. 2018 Oct - Dec;52(5-6):328-332. doi: 10.1080/21681805.2018.1551244. Epub 2019 Feb 14.


First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ.

Cancer Causes Control. 2019 Mar;30(3):259-269. doi: 10.1007/s10552-019-1133-5. Epub 2019 Jan 30.


A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, Inman BA, Armstrong AJ, George D, Westman E, Lin PH.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):428-437. doi: 10.1038/s41391-019-0126-5. Epub 2019 Jan 21.


Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

JAMA Oncol. 2019 Apr 1;5(4):529-536. doi: 10.1001/jamaoncol.2018.5904.


Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.

Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Urol Oncol. 2019 Apr;37(4):289.e11-289.e17. doi: 10.1016/j.urolonc.2018.12.004. Epub 2018 Dec 28.


ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.


Supplemental Content

Loading ...
Support Center